Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

2.65USD
3:59pm EST
Change (% chg)

$-0.05 (-1.85%)
Prev Close
$2.70
Open
$2.70
Day's High
$2.72
Day's Low
$2.65
Volume
35,339
Avg. Vol
53,621
52-wk High
$4.36
52-wk Low
$2.41

Select another date:

Mon, Oct 3 2016

BRIEF-Acelrx Pharma says amended loan and security deal with Hercules Tech II and Hercules Capital Inc

* Among other things, amendment extends interest-only period from October 1, 2016 to April 1, 2017 - SEC filing

BRIEF-AcelRx Pharmaceuticals initiates late-stage study of its painkiller

* Initiates phase 3 study of Zalviso in patients with moderate-to-severe acute post-operative pain Source text for Eikon: Further company coverage:

AcelRx's opioid painkiller succeeds in key study

AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

UPDATE-1-AcelRx's opioid painkiller succeeds in key study

Sept 15 AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

BRIEF-Acelrx reports positive results for ARX-04 in Phase 3 registration trial

* Reports positive results for ARX-04 (sufentanil sublingual tablet, 30 mcg), including in elderly patients and patients with organ impairment, in third Phase 3 registration trial, SAP303

BRIEF-Acelrx Pharmaceuticals posts results from phase 3 study of ARX-04

* Acelrx pharmaceuticals presents results from phase 3 study of ARX-04 in the emergency department at the international society for burn injuries

BRIEF-AcelRx Pharmaceuticals says ARX-04 phase 3 trial met primary endpoint

* Overall ARX-04 was well tolerated in study, with 79% of patients reporting no adverse events

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.24

* Acelrx Pharmaceuticals provides corporate update and reports second quarter and six months 2016 financial results

Select another date: